About: IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study
Creator	Shalhoub, Sarah Mushtaq, Adnan Simhairi, Raed Al-Jiffri, Abdullah Farahat, Fayssal Shamma, Omar Siddiqi, Nauman
Source	Medline; PMC
abstract	OBJECTIVES: Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with significant mortality. We examined the utility of plasma MERS-CoV PCR as a prognostic indicator and compared the efficacies of IFN-α2a and IFN-β1a when combined with ribavirin in reducing MERS-CoV-related mortality rates. METHODS: We retrospectively analysed 32 patients with confirmed MERS-CoV infection, admitted between April 2014 and June 2014, by positive respiratory sample RT–PCR. Plasma MERS-CoV RT–PCR was performed at the time of diagnosis for 19 patients. RESULTS: The overall mortality rate was 69% (22/32). Ninety percent (9/10) of patients with positive plasma MERS-CoV PCR died compared with 44% (4/9) of those with negative plasma MERS-CoV PCR. Mortality rate in patients who received IFN-α2a was 85% (11/13) compared with 64% (7/11) in those who received IFN-β1a (P = 0.24). The mortality rate in patients with renal failure (14), including 8 on haemodialysis, was 100%. Age >50 years and diabetes mellitus were found to be significantly associated with mortality (OR = 26.1; 95% CI 3.58–190.76; P = 0.001 and OR = 15.74; 95% CI 2.46–100.67; P = 0.004, respectively). The median duration of viral shedding in patients who recovered was 11 days (range 6–38 days). Absence of fever was noted in 5/32 patients. CONCLUSIONS: Plasma MERS-CoV RT–PCR may serve as an effective tool to predict MERS-CoV-associated mortality. Older age and comorbid conditions may have contributed to the lack of efficacy of IFN-α2a or IFN-β1a with ribavirin in treating MERS-CoV. Absence of fever should not exclude MERS-CoV.
has issue date	2015-04-21(xsd:dateTime)
bibo:doi	10.1093/jac/dkv085
bibo:pmid	25900158
has license	no-cc
sha1sum (hex)	fa03d17fe7407dbe72f66d7fe211a5f2311c819a
schema:url	https://doi.org/10.1093/jac/dkv085
resource representing a document's title	IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study
has PubMed Central identifier	PMC7202429
has PubMed identifier	25900158
schema:publication	J Antimicrob Chemother
resource representing a document's body	covid:fa03d17fe7407dbe72f66d7fe211a5f2311c819a#body_text
is schema:about of	named entity 'efficacies' named entity 'April' named entity 'PCR' named entity 'mortality' named entity 'sample' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'OBJECTIVES' named entity 'A2A' named entity 'INFECTION' named entity 'MERS-CoV' named entity 'patients' named entity '2014' named entity '2014' named entity 'ribavirin' named entity 'prognostic indicator' named entity 'mortality rates' named entity 'Plasma' named entity 'PCR' named entity 'Middle East respiratory syndrome coronavirus' named entity 'King Abdulaziz Medical City' named entity 'Saudi Arabia' named entity 'IBM SPSS Statistics' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'Clinical features' named entity 'respiratory tract' named entity 'IFN' named entity '10.5' named entity 'MERS-CoV' named entity 'PCR' named entity 'MERS-CoV' named entity 'fever' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'fever' named entity 'Plasma' named entity 'MERS-CoV' named entity 'diabetes mellitus' named entity 'ribavirin' named entity 'MERS-CoV' named entity 'viral shedding' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'haemodialysis' named entity 'RT-PCR' named entity 'oxygen' named entity 'mortality rates' named entity 'pneumonia' named entity 'MERS-CoV' named entity 'end-stage renal disease' named entity 'impaired renal function' named entity 'Ribavirin' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'IFN' named entity 'mortality rates' named entity 'log-rank test' named entity 'PCR' named entity 'RT-PCR' named entity '1 May 2014' named entity 'ribavirin' named entity 'MERS-CoV' named entity 'sputum' named entity 'RT-PCR' named entity '1, 2' named entity 'IFN' named entity 'aspirate' named entity 'aspirate' named entity 'MERS-CoV' named entity 'ribavirin' named entity 'ribavirin' named entity 'plasma' named entity 'plasma'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software